Introduction
============

During the last 20 years, the world has witnessed an unparalleled increase in the incidence of diabetes mellitus, which has been identified as a threatening epidemic ([@b64]; [@b13]). Diabetic complications now account for the greater part of diabetes-related morbidity and healthcare costs ([@b6]; [@b2]; [@b8]). This holds especially true for the diabetic foot ([@b35]; [@b6]; [@b8]). Indeed, diabetes is the major cause of nontraumatic lower-extremity amputations, reducing patient survival ([@b58]) and inflicting an enormous financial burden on society ([@b8]). It is not long ago that the International Working Group on the Diabetic Foot estimated the loss of a foot or leg attributable to diabetes every 30 seconds in the world ([@b2]). Naturally, amputations are associated with substantial direct (ie, hospitalization and medication) as well as indirect (ie, loss of working days) costs ([@b6]; [@b8]).

It is now beyond dispute that the vast majority of amputations result from prior ulceration ([@b6]; [@b8]). Diabetic foot ulcers have a complex pathophysiology and are notoriously difficult to heal ([@b6]; [@b2]; [@b8]; [@b22]). The strategy to improve healing rates is based on the management of peripheral arterial disease, relief of high-pressure areas, aggressive debridement, and infection control ([@b61]; [@b6]; [@b17]). At the same time, new treatments (growth factors, bioengineered skin substitutes, extracellular matrix proteins, and various other products) are continuously being explored ([@b28]; [@b48]). This article reviews the use of becaplermin in the treatment of diabetic neuropathic foot ulcers. Becaplermin is recombinant platelet-derived growth factor commercially available as a gel form of 100 μg/g becaplermin. At the moment, it represents the only growth factor approved by American and European authorities for use in the treatment of foot ulceration.

Diabetic foot ulcers
====================

Overall, one out of four diabetic patients runs the risk of developing foot ulceration in his lifetime ([@b50]). Foot ulcers result from the composite interaction of three major entities: ischemia, neuropathy, and infection ([@b49]; [@b6]; [@b17]; [@b18]; Singh et al 2005). Ischemia is ascribed to peripheral arterial disease, which is exceedingly frequent in diabetes, and leads to poor nutrient supply to peripheral tissue ([@b55]; [@b17]). Neuropathy deprives patients of protective sensation, so that trauma (such as induced by stepping on a sharp object or, simply, due to ill-fitting shoes) may be unrecognized, leading to continuing tissue destruction ([@b49]; [@b7]; [@b17]; Singh et al 2005). Moreover, it leads to various foot deformities, resulting in abnormal focal pressure distribution on the plantar aspect of the foot ([@b49]; [@b7]; [@b17]). Accordingly, some plantar sites have very high pressures and can easily develop ulcers ([@b49]; [@b7]; [@b17]). Ultimately, more than half of chronic foot ulcers become infected ([@b46]). Infection is usually polymicrobial, with a combination of Gram-positive cocci, Gram-negative bacteria, and anaerobes, and may rapidly lead to necrosis ([@b17]; [@b19]).

A clinically useful classification is into two categories: neuroischemic and neuropathic foot ulcers ([@b61]; [@b18]). In the former, neuropathy and ischemia coexist. The ulcer is usually located on the margins of the foot, has irregular shape and is typically painful, although peripheral neuropathy in some patients reduces or obviates pain. The foot is not warm, but may be cold and pulseless ([@b61]; [@b18]). The latter is most commonly found in high-pressure areas, notably prominent metatarsal heads and apices of toes ([@b61]; [@b18]). It is usually painless, surrounded by heavy callus formation and may be somewhat circular with a raised rim. The foot is warm, with intact pulses, while sensation is diminished ([@b61]; [@b7]; [@b18]). This distinction is of vital importance, because treatment differs according to etiology ([@b61]; [@b18]).

Overview of normal healing
==========================

Normal healing is a complex process requiring the collaboration of numerous cells involved in the four overlapping phases of the healing cascade ([@b31]; [@b28]; [@b22]). These phases are, by tradition, classified as hemostasis, inflammation, migration/proliferation (otherwise known as maturation), and remodelling ([Table 1](#tbl1){ref-type="table"}) ([@b31]; [@b28]; [@b22]) and will be very briefly described below. Immediately after injury, vasoconstriction and platelet activation occur (hemostasis) ([@b28]; [@b22]). Platelets are the initiators of the clotting cascade, but they also release growth factors (including platelet-derived growth factor, PDGF) and cytokines to attract other cells required for healing. In the next phase, inflammatory cells (mainly neutrophils and macrophages, but also lymphocytes) enter the wound site by chemotaxis ([@b28]; [@b22]). Neutrophils eliminate necrotic debris; macrophages remove bacteria and necrotic tissue, and they secrete growth factors to facilitate continuation of healing; lymphocytes have a less clearly defined role. In the subsequent phase, migration/proliferation, wound contraction predominates ([@b28]; [@b22]). Tissue integrity is restored by fibroplasia, new vessel formation (neovascularization), and skin re-epithelialization ([@b28]; [@b22]). Finally, remodeling is a slow dynamic process, in which cell density and vascularization are diminished, while the total amount and the tensile strength of collagen increase ([@b28]; [@b22]). Moreover, collagen fibers are progressively realigned and may lead to a variable amount of scarring ([@b31]; [@b28]; [@b22]).

###### 

Overview of the phases of normal wound healing ([@b31]; [@b28]; [@b22])

  Phase                                                      Main cell types                                    Main activity
  ---------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------
  Coagulation                                                Platelets                                          Vasoconstriction, clot formation, secretion of growth factors, and cytokines
  Inflammation                                               Leukocytes (neutrophils, monocytes, macrophages)   Chemotaxis of inflammatory cells, eradication of bacteria, and necrotic debris
  Migration/proliferation[\*](#tf1-1){ref-type="table-fn"}   Keratinocytes, fibroblasts, endothelial cells      New vessel formation, fibroplasia
  Remodeling                                                 Fibroblasts                                        Wound contraction, realignment of collagen fibers to increase tensile strength, scarring

**Notes:** Otherwise known as maturation.

Impaired healing in diabetes
============================

Healing of foot ulcers is characteristically impaired in diabetes ([@b17]; [@b28]; [@b22]). Therefore, patients often present with chronic, refractory, or recurrent foot ulcers ([@b17]; [@b28]). The detrimental effect of diabetes on healing may be described as being exerted at two levels. The first level comprises factors extrinsic to the wound itself, while the second level consists of intrinsic factors. Extrinsic factors can be summarized as the aforementioned triad of peripheral arterial occlusive disease, neuropathy, and infection ([@b17]; [@b28]). Naturally, peripheral arterial occlusive disease results in diminished oxygen supply to the components of the wound ([@b6]; [@b17]). If ischemia is severe, it may even prevent intravenously administered antibiotics from achieving adequate concentration in the wound ([@b19]). Peripheral autonomic neuropathy may lead to disruption of the neurogenic control of small blood vessels, thereby resulting in diminished inflammatory response and impaired wound healing ([@b45]; [@b19]). Infection complicates diabetic foot ulceration and aggravates cellular hypoxia by raising metabolic demands and by causing a neutrophilic vasculitis ([@b17]; [@b28]).

Intrinsic factors are now being increasingly investigated. It is thought that they affect local growth factors and miscellaneous wound healing constituents. Diabetic foot ulcers have been shown to exhibit abnormal or reduced expression of growth factors ([@b28]; [@b22]). Diminished biologic action of growth factors due to nonenzymatic glycosylation is also a contributory factor ([@b28]). Some chronic diabetic foot ulcers also do not respond to local growth factors ([@b29]; [@b4]). At a cellular level, reduced neutrophil chemotaxis, defective fibroblast action, and impaired capacity of other cell populations for migration and proliferation ([@b29]; [@b28]; [@b5]) have been found. Finally, poor co-ordination of matrix metalloproteases with their tissue inhibitors exacerbates the impairment of healing ([@b28]; [@b5]).

Interestingly, hyperglycemia substantially affects both extrinsic and intrinsic factors. Not only has impaired metabolic control been associated with increased prevalence of diabetic complications, notably neuropathy and vascular disease ([@b6]; [@b2]; [@b8]), but it also impacts on the healing process itself ([@b44]). Indeed, the magnitude of hyperglycemia adds to the perturbation of the normal healing cascade. This negative effect is mediated via impaired function of intrinsic healing factors and via disordered participation of the cellular components of healing ([@b5]). The recognition of this effect of hyperglycemia has obvious implications in clinical practice, which emphasizes the need for optimizing glycemic control.

Overview of the treatment for diabetic foot ulcers
==================================================

Treatment of diabetic foot ulcers needs to address the three major causal factors: ischemia, neuropathy, and infection ([@b61]; [@b6]; [@b17]). In the neuroischemic foot, it is imperative to diagnose ischemia immediately and to restore normal blood flow to the limb. This can be achieved either surgically (bypass graft surgery) or intravascularly (percutaneous transluminal angioplasty) as required ([@b55]; [@b17]). In the neuropathic foot, the ulcerated area needs to be off-loaded with casts and cushioning insoles ([@b6]; [@b17]). Off-loading is combined with surgical debridement, which has been documented to promote granulation and wound closure ([@b17]; [@b57]). In both neuroischemic and neuropathic ulcers, a high index of suspicion for the diagnosis of infection is necessary to enable timely institution of antibiotics, choosing initially broad-spectrum agents and, subsequently, guided by appropriate cultures. These are usually swab cultures, although some authorities prefer deep tissue specimens ([@b17]; [@b19]). Advances in these treatment modalities have led to improvement in healing rates ([@b17]). However, a significant number of ulcers (as high as 49%) still may fail to heal ([@b38]), indicating the need for further improvement.

Why use growth factors to promote healing?
==========================================

Growth factors have been shown to be omnipresent throughout the healing process ([@b32]; [@b12]). They act by binding to specific receptors in the plasma membranes of target cells, thereby activating signal transduction mechanisms ([@b32]; [@b12]). At the cellular level, growth factors mediate macrophage migration, neovascularization, collagen synthesis, fibroblast proliferation, as well as final re-epithelialization ([@b44]). Importantly, each growth factor acts on several cell lines, and this interaction enhances healing ([@b32]; [@b12]). The need to improve the aforementioned cellular functions has led to the ongoing exploration of several growth factors ([@b32]; [@b12]). The rationale for this investigation is that while the restoration of a normal healing cascade may be elusive, any improvement in healing rates obtained with growth factors would be useful ([@b32]; [@b38]).

The main growth factors involved in healing are: PDGF, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factors (IGF~1~, IGF~2~), epidermal growth factor (EGF), and transforming growth factor β (TGF-β) ([@b32]; [@b28]; [@b22]). To date, only PDGF has been approved by the US Food and Drug Administration and European authorities ([@b44]). Other growth factors include granulocyte-colony stimulating factor (GCSF) and nerve growth factor (NGF) ([@b44]). Initially, GCSF yielded very good results in infected diabetic foot ulcers without severe ischemia, but these were not replicated in the following studies, so that its clinical utility is rather questionable ([@b3]; [@b14]; [@b44]). Experience with the other growth factors remains very limited ([@b44]).

PDGF: a protagonist in healing
==============================

Platelet-derived growth factor is mainly secreted by the platelets' α-granule, but it is also produced by other cells involved in early wound healing, ie, macrophages, endothelial cells, fibroblasts, and keratinocytes ([@b44]). PDGF is a powerful chemoattractant and mitogen, exerting its action on fibroblasts, smooth muscle cells, and endothelial cells ([@b44]). It also induces production of fibronectin and hyaluronic acid. There is a synergistic effect between PDGF and EGF, as well as TGF-β, and so PDGF has a pivotal role at all stages of wound healing ([@b40]; [@b44]).

PDGF is a dimer consisting of A and/or B chains, held together by a disulfide bond. Three isomers (AA, BB, and AB) have been isolated. The most common and potent isomer is the BB isomer ([@b40]; [@b44]). Therefore, this isomer is the one used in the management of foot ulcers ([@b40]; [@b44]).

At present, recombinant PDGF is produced by DNA technology via incorporation of the gene for the β-chain of human PDGF into the yeast *Saccharomyces cerevisiae*. The resultant homodimeric protein, becaplermin, has a biological activity similar to the endogenous PDGF-BB ([@b44]). A gel form of 100 μg/g becaplermin (Regranex^®^ gel; Ortho-McNeil Pharmaceutical, Inc, Titusville, NJ, USA) has been approved by the US Food and Drug Administration for the treatment of diabetic neuropathic ulcers with adequate peripheral circulation ([@b44]).

Efficacy of becaplermin gel in neuropathic diabetic foot ulcers
===============================================================

The efficacy of becaplermin gel in the management of neuropathic ulcers has been documented by a number of randomized controlled trials, reviewed in more detail elsewhere ([@b44]). In these, 922 patients were studied in total ([@b56]; [@b53]; [@b54]; [@b62]; [@b63]; [@b15]; [@b20]). Steed conducted the first randomized, double-blind placebo-controlled trial ([@b56]). He enrolled 118 patients, randomized to topical application of 30 μg/g becaplermin (N = 61) or placebo (N = 57). At the end of the study, 48% (29/61) of ulcers healed in the becaplermin group vs. 25% (14/57) in the placebo group (p = 0.01) ([@b56]). There was also a non-significant trend (p = 0.09) for a greater median reduction in wound area in the becaplermin group (98.8%) as compared with the placebo group (82.1%).

[@b62] conducted a phase III randomized double-blind placebo-controlled trial on the efficacy and safety of becaplermin gel 30 μg/g (N = 132) vs. becaplermin gel 100 μg/g (N = 123) vs. placebo (N = 127) ([@b62]). This work showed that becaplermin gel 100 μg/g added to standard wound care significantly increased healing rates and decreased time to complete healing ([@b62]). Healing rates were 49.5% (61/123) in patients receiving becaplermin gel 100 μg/g, 36.3% (48/132) in those receiving becaplermin gel 30 μg/g, and 34.6% (44/127) in those receiving placebo. There was a significant difference (p = 0.007) between high-dose becaplermin and placebo ([@b62]).

[@b15] compared three treatment regimens, ie, good wound care alone (N = 68), topical carboxymethylcellulose gel (N = 70), and becaplermin gel 100 μg/g added to standard wound care (N = 34). This study was statistically underpowered. However, becaplermin-treated patients did achieve a slightly higher healing rate (44.1%) in comparison with carboxymethylcellulose-treated patients (35.7%) and those receiving standard wound care alone (22%) ([@b15]).

A multi-center phase IIIB open-label study examined the efficacy and safety of becaplermin gel 100 μg/g in 134 patients ([@b20]). It was shown that as high as 57.5% of ulcers managed to heal with a mean time to wound closure of 63 days and a 21% six-month recurrence rate ([@b20]).

[@b54] carried out a combined analysis based on all 922 patients recruited in the aforementioned studies ([@b56]; [@b62]; [@b15]; [@b20]). This analysis provided evidence for a significant beneficial effect of becaplermin on healing. Indeed, becaplermin gel 100 μg/g significantly (p = 0.0007) increased the likelihood of complete wound healing in comparison with placebo by 39% (50% vs. 36%, respectively). The drug also significantly (p = 0.01) decreased the time to heal as compared with placebo by 30% (14.1 weeks vs. 20.1 weeks, respectively) ([@b54]).

[Table 2](#tbl2){ref-type="table"} summarizes the clinical trials on becaplermin. In all studies, inclusion criteria were: a) chronic foot ulcer of duration ≥8 weeks); b) adequate arterial perfusion as documented by Ankle-Brachial Pressure Index \>0.70 and/or transcutaneous partial pressure of oxygen ≥30 mmHg; c) absence of infection ([@b44]).

###### 

Clinical trials of PDGF in diabetic foot ulcers. Copyright © 2007 SAGE Publications. Reproduced with permission from [@b44]. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? *Int J Low Extrem Wounds*, 6:37--53

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Platelet-derived growth factor*                                                                                                                                          
  ---------------------------------- ------ ------------------------------------------------ ------------------------------------------------------------------------------ --------------------------------------------------------------
  Steed                              1995   Double blind placebo controlled                  Topical PDGF gel 30 μg/g vs. placebo                                           Complete ulcer closure at 20 weeks: 48% vs. 25%, p = 0.01

  Wieman                             1998   Double blind placebo controlled                  Topical PDGF gel 100 μg/g vs. 30 vs. μg/g vs. placebo                          Complete ulcer closure: 49.5% vs. 36% vs. 35%, p = 0.007\
                                                                                                                                                                            Mean time to heal: 86 days (100 μg/g) vs. 127 days (placebo)

  D'Hemercourt                       1998   Randomized double-blind placebo-controlled       Topical PDGF gel 100 μg/g vs. carboxymethylcellulose gel vs. good ulcer care   Complete ulcer closure: 44.1% vs. 35.7% vs. 22%

  Embil                              2000   Phase IIIB open-label                            Safety of topical PDGF gel 100 μg/g                                            Complete ulcer closure: 57.5% Mean time to heal: 63 days

  Smiell                             1999   Meta-analysis[\*](#tf2-1){ref-type="table-fn"}   Topical PDGF gel 100 μg/g vs. placebo                                          Complete ulcer closure: 50% vs. 36%, p = 0.0007\
                                                                                                                                                                            Mean time to heal: 14.1 weeks vs. 20.1 weeks, p = 0.01
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Meta-analysis of the studies by [@b56], [@b62], [@b15], and [@b20].

Safety of becaplermin gel in neuropathic diabetic foot ulcers
=============================================================

In all clinical trials, the safety profile of becaplermin has consistently been found excellent, comparable with that of placebo ([@b44]). The clinical safety of the drug has also been specifically examined by [@b53]. It was demonstrated that rash occurred in 2% of becaplermin-treated patients and in 1% of those receiving placebo. Similarly, cardiovascular, respiratory, musculoskeletal and central or peripheral nervous system disorders did not differ between becaplermin- and placebo-treated subjects. Moreover, there were no neutralizing antibodies against becaplermin ([@b53]).

Cost-Effectiveness of becaplermin gel in neuropathic diabetic foot ulcers
=========================================================================

Several authors have examined the cost-effectiveness of becaplermin ([@b47]; [@b23]; [@b30]; [@b1]; [@b51]). The drug has been shown to be cost-effective in Sweden ([@b47]), in four European countries (Sweden, Switzerland, UK, and France) ([@b23]) and in the USA ([@b30]). In the USA, the addition of becaplermin is associated with an initial higher cost, but this effectively reduces expenses resulting from more prolonged treatment, namely office visits and dressings, as well as complication rates ([@b1]). Indeed, adding up to 20 weeks of becaplermin to best medical care over 12 months resulted in 26 fewer ulcer-days per patient, equating to an avoided cost-effectiveness ratio of US\$6 per ulcer-day ([@b51]). A cost-effectiveness study of becaplermin in other parts of the world, including developing countries, is missing ([@b44]).

Becaplermin gel in actual clinical practice: expectations still not met
=======================================================================

Although becaplermin has been shown to significantly improve healing rates in small randomized controlled trials, this efficacy has not yet translated to positive clinical experience ([@b44]). This discrepancy may be ascribed to the fact that randomized trials are conducted under tightly controlled conditions, whereas clinicians encounter patients in actual practice, rather than in the ideal world ([@b44]). Consequently, efficacy of the drug under study in the setting of a controlled trial does not necessarily translate into effectiveness of the same drug in everyday clinical situation. This prompted [@b39] to examine the effectiveness of becaplermin in actual clinical practice. Their study included 24,898 subjects with neuropathic foot ulceration between 1998 and 2004, of whom 2394 (9.6%) received becaplermin ([@b39]). Healing rates were 33.5% and 25.8% in the becaplermin and control group respectively (p \< 0.0001) ([@b39]). Accordingly, becaplermin increased the likelihood of healing by 32% (RR = 1.32). Moreover, amputation rates were significantly (p \< 0.0001) lower in the becaplermin (4.9%) than in the control group (6.4%), despite the fact that patients receiving becaplermin had considerable adverse risk factors for healing (increased wound duration and size, increased wound grade at initial visit) ([@b39]).

The study by [@b39] again suggested that becaplermin should be expected to improve healing rates in practice. However, this expectation has not been met, so that the drug is still not widely used. In line with this clinical wisdom, the International Working Group on the Diabetic Foot has in a very recent international consensus statement suggested that evidence justifying the use of becaplermin remains to be confirmed ([@b27]). Obviously, further improvement is required to utilize the beneficial potential of becaplermin in everyday clinical situations.

Implications for further improvement with becaplermin
=====================================================

The recognition that routine clinical experience with becaplermin in the management of diabetic foot ulcers has been less successful than hoped for ([@b27]; [@b44]) has led to the exploration of potential areas of improvement with the use of this agent. It has been hypothesized that application of a growth factor in a liquid or gel form might not ensure availability to the healing cells in the wound site ([@b36]). Hence, alternative modes of growth factor delivery have been explored ([@b21]; [@b33]; [@b9]; [@b34]). Encapsulation of growth factors into red blood cells or microspheres, application of skin substitutes over-expressing growth factors, genetic manipulation, and intra-arterial growth factor infusion represent the most important alternatives ([@b21]; [@b33]; [@b9]; [@b34]). Most of the work with alternative modes of growth factor delivery is still experimental, and clinical experience is eagerly awaited ([@b44]).

Combination of becaplermin with other growth factors to enhance healing is a further attractive notion ([@b44]). This combination is justified on the basis of the naturally occurring interaction between growth factors during normal healing ([@b44]). A study of the effect of growth factors on healing in full-thickness skin wounds created on the backs of diabetic mice has, indeed, provided evidence for a synergistic action of the PDGF and TGF-α combination ([@b10]).

Additionally, the option of longer exposure time of the wound to becaplermin to optimize the frequency of drug application and dressing changes is also highly interesting ([@b11]). However, this possibility remains hitherto unexplored ([@b44]).

Finally, it should not escape our notice that becaplermin has been mostly studied in patients with type 2 diabetes. This type of diabetes is now showing an unprecedented epidemic across the world ([@b64]; [@b13]). Thus, the greater proportion of foot ulcers is encountered in patients with type 2 diabetes ([@b6]; [@b2]; [@b8]). However, it might be useful to examine if there is any difference in the efficacy of becaplermin between patients with type 1 and those with type 2 diabetes.

Conclusions
===========

The diabetic foot continues to be a major cause of morbidity across the world, and there is a fundamental need to improve the outcomes ([@b2]; [@b42]). The development of growth factors to promote wound healing represents an important step forward, but there is still a long way to go. Becaplermin is the only growth factor currently approved for use in diabetic foot ulcers ([@b44]). Nonetheless, it may only be used in neuropathic ulcers with adequate peripheral circulation ([@b44]). More importantly, it is a widespread clinical impression that its success in everyday practice has been less triumphant than might have been anticipated on the grounds of randomized controlled trials ([@b27]; [@b44]). Last but not least, becaplermin is an expensive medication. Even though it has repeatedly been estimated as cost-effective in the Western world, its high cost may be prohibitive in developing countries, which are responsible for a great part of the global burden of the diabetic foot ([@b2]; [@b8]).

Clearly, further work is needed to render becaplermin a more effective tool. Some of the potential areas of improvement have already been identified as improved drug delivery to the ulcer and combination therapy with other growth factors to achieve a synergistic effect ([@b10]; [@b11]; [@b34]). Of equal importance is the necessity for a more precise definition of the role of becaplermin in the overall treatment strategy for the diabetic foot ([@b44]). Clinicians need evidence-based guidelines specifying when to use standard care and when to consider the use of this agent. Should they, for instance, only use becaplermin in ulcers that have already proved refractory to established treatment or should they try to predict which ulcers are more difficult to heal ([@b37]) and might benefit from earlier initiation of growth factor treatment?

Finally, it should not be underestimated that the use of becaplermin, as indeed of every new therapeutic modality, should not be practiced alone, but be incorporated in a holistic strategic approach. Essentially, only multidisciplinary foot clinics have demonstrated that the reduction of lower-limb amputations is possible ([@b16]; [@b24]; [@b25], [@b26]; [@b59]). Knowledge needs to be implemented more vigorously, coupled with constant education of patients and physicians alike, emphasizing on primary and secondary prevention ([@b41], [@b43]). Numerous obstacles to effective foot care still prevail and need to be abolished to reduce amputations ([@b60]; [@b43]).
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